Pasar al contenido principal

SUPERAR LA EVASION INMUNE EN CANCER DE PULMON KRAS MUTADO

PID2021-122797OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.

  • Fernández-García, Fernando
  • Fernández-Rodríguez, Ana
  • Fustero-Torre, Coral
  • Piñeiro-Yáñez, Elena
  • Wang, Haiyun
  • Lechuga, Carmen G
  • Callejas, Sergio
  • Álvarez, Rebeca
  • López-García, Alejandra
  • Esteban-Burgos, Laura
  • Salmón, Marina
  • San Román, Marta
  • Guerra, Carmen
  • Ambrogio, Chiara
  • Drosten, Matthias
  • Santamaría, David
  • Al-Shahrour, Fatima
  • Dopazo, Ana
  • Barbacid, Mariano
  • Musteanu, Mónica
Lung cancer is the leading cause of cancer mortality worldwide. KRAS oncogenes are responsible for at least a quarter of lung adenocarcinomas, the main subtype of lung cancer. After four decades of intense research, selective inhibitors of KRAS oncoproteins are finally reaching the clinic. Yet, their effect on overall survival is limited due to the rapid appearance of drug resistance, a likely consequence of the high intratumoral heterogeneity characteristic of these tumors. In this study, we have attempted to identify those functional alterations that result from KRAS oncoprotein expression during the earliest stages of tumor development. Such functional changes are likely to be maintained during the entire process of tumor progression regardless of additional co-occurring mutations. Single-cell RNA sequencing analysis of murine alveolar type 2 cells expressing a resident oncogene revealed impairment of the type I interferon pathway, a feature maintained throughout tumor progression. This alteration was also present in advanced murine and human tumors harboring additional mutations in the p53 or LKB1 tumor suppressors. Restoration of type I interferon (IFN) signaling by IFN-β or constitutive active stimulator of interferon genes (STING) expression had a profound influence on the tumor microenvironment, switching them from immunologically "cold" to immunologically "hot" tumors. Therefore, enhancement of the type I IFN pathway predisposes KRAS mutant lung tumors to immunotherapy treatments, regardless of co-occurring mutations in p53 or LKB1.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis

  • Rodrigo-Faus, María
  • Vincelle-Nieto, África
  • Vidal, Natalia
  • Puente, Javier
  • Saiz-Pardo, Melchor
  • López-García, Alejandra
  • Mendiburu-Eliçabe, Marina
  • Palao, Nerea
  • Baquero, Cristina
  • Linzoain-Agos, Paula
  • Cuesta, Ángel M.
  • Qu, Hui-Qi
  • Hakonarson,Hakon
  • Musteanu, Mónica
  • Reyes-Palomares, Armando
  • Porras, Almudena
  • Bragado, Paloma
  • Gutiérrez-Uzquiza, Álvaro
Due to the limited effectiveness of current treatments, the survival rate of patients with metastatic castration-resistant prostate cancer (mCRPC) is significantly reduced. Consequently, it is imperative to identify novel therapeutic targets for managing these patients. Since the invasive ability of cells is crucial for establishing and maintaining metastasis, the aim of this study was to identify the essential regulators of invasive abilities of mCRPC cells by conducting two independent high-throughput CRISPR/Cas9 screenings. Furthermore, some of the top hits were validated using siRNA technology, with protein arginine methyltransferase 7 (PRMT7) emerging as the most promising candidate. We demonstrated that its inhibition or depletion via genetic or pharmacological approaches significantly reduces invasive, migratory and proliferative abilities of mCRPC cells in vitro. Moreover, we confirmed that PRMT7 ablation reduces cell dissemination in chicken chorioallantoic membrane and mouse xenograft assays. Molecularly, PRMT7 reprograms the expression of several adhesion molecules by methylating various transcription factors, such as FoxK1, resulting in the loss of adhesion from the primary tumor and increased motility of mCRPC cells. Furthermore, PRMT7 higher expression correlates with tumor aggressivity and poor overall survival in prostate cancer patients. Thus, this study demonstrates that PRMT7 is a potential therapeutic target and potential biomarker for mPCa., This work was funded by Comunidad de Madrid under projects 2017-T1/BMD-5468 and 2021-5A/BMD-20956; Grants (PID2020-117650RA-I00 (AGU), PID2019-104143RB-C22 (AP), PID2019-104991RB-I00 (PB) and PID2021-122797OB-I00 (MM)) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; and ARP and AVN have been supported and granted by the Regional Programme of Research and Technological Innovation for Young Doctors UCM-CAM (PR65/19–22460)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors

  • Fernández-García, Fernando
  • Fernández-Rodríguez, Ana
  • Fustero-Torre, Coral
  • Piñeiro-Yáñez, Elena
  • Wang, Haiyun
  • Lechuga, Carmen G.
  • Callejas, Sergio
  • Álvarez, Rebeca
  • López-García, Alejandra
  • Esteban-Burgos, Laura
  • Salmón, Marina
  • Román, Marta San
  • Guerra, Carmen
  • Ambrogio, Chiara
  • Drosten, Matthias
  • Santamaria, David
  • Al-Shahrour, Fátima
  • Dopazo, Ana
  • Barbacid, Mariano
  • Musteanu, Mónica
Lung cancer is the leading cause of cancer mortality worldwide. KRAS oncogenes are responsible for at least a quarter of lung adenocarcinomas, the main subtype of lung cancer. After four decades of intense research, selective inhibitors of KRAS oncoproteins are finally reaching the clinic. Yet, their effect on overall survival is limited due to the rapid appearance of drug resistance, a likely consequence of the high intratumoral heterogeneity characteristic of these tumors. In this study, we have attempted to identify those functional alterations that result from KRAS oncoprotein expression during the earliest stages of tumor development. Such functional changes are likely to be maintained during the entire process of tumor progression regardless of additional co-occurring mutations. Single-cell RNA sequencing analysis of murine alveolar type 2 cells expressing a resident Kras oncogene revealed impairment of the type I interferon pathway, a feature maintained throughout tumor progression. This alteration was also present in advanced murine and human tumors harboring additional mutations in the p53 or LKB1 tumor suppressors. Restoration of type I interferon (IFN) signaling by IFN-β or constitutive active stimulator of interferon genes (STING) expression had a profound influence on the tumor microenvironment, switching them from immunologically “cold” to immunologically “hot” tumors. Therefore, enhancement of the type I IFN pathway predisposes KRAS mutant lung tumors to immunotherapy treatments, regardless of co-occurring mutations in p53 or LKB1., This work was supported by grants from the European Research Council (ERC-AG/695566, THERACAN) to M.B. and grants from the Spanish Ministry of Science, Innovation and Universities cofounded by the European Regional Development Fund “A way of making Europe”: RTI2018-094664-B-I00 to M.B. and M.M. and PID2021-122797OB-I00 to M.M. M.B. is a recipient of an Endowed Chair from the AXA Research Fund. M.M. is recipient of a “Ramón y Cajal” fellowship from the Spanish Ministry of Science, Innovation and Universities. F.F.-G. and A.F.-R. were supported by a Formación de Profesorado Universitario fellowship from the Spanish Ministry of Science, Innovation and Universities., Peer reviewed